Quintrio
Home

Stock overview

MDxHealth SA Ordinary Shares

MDXH

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Last trade $0.1525
Day change +$0.0035 (+2.35%)
Day range $0.144 – $0.16
Volume 702,868
Market cap $14M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for MDXH.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for MDXH.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

MDxHealth SA (MDXH) Reports Q3 Loss, Misses Revenue Estimates

MDxHealth SA reported a quarterly loss of $0.16 per share, significantly worse than the consensus estimate of $0.07, and missed revenue expectations by 20.31% with $22.71 million in revenues. The stock has declined 95.9% year-to-date and received a Zacks Rank #3 (Hold) rating. The company has consistently underperformed consensus estimates over the last four quarters.

Zacks Investment Research

Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates

Senseonics Holdings (SENS) reported a quarterly loss of $0.5 per share, slightly missing consensus estimates of $0.49, though revenues of $19.56 million exceeded expectations by 19.06%. The company has outperformed the S&P 500 by 55.6% year-to-date but maintains a Zacks Rank #3 (Hold) rating with mixed estimate revisions. MDxHealth SA is expected to report results on November 12 with anticipated quarterly losses.

GlobeNewswire Inc.

Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency

Mdxhealth SA (NASDAQ: MDXH) received a notification from Nasdaq on July 20, 2026, indicating non-compliance with the minimum market value requirement of $35 million for continued listing on The Nasdaq Capital Market. The company has until January 19, 2027 (180 calendar days) to regain compliance by achieving a market value exceeding $35 million for at least 10 consecutive business days. The deficiency does not currently impact the company's listing status, and business operations remain unaffected.

GlobeNewswire Inc.

Mdxhealth Reports Q1-2026 Results

Mdxhealth (NASDAQ: MDXH) reported Q1-2026 revenue of $27.4 million, up 13% year-over-year, but announced the discontinuation of its Resolve UTI business and Plano, Texas laboratory operations due to uncertain reimbursement landscape and a Medicare policy reversal. The company is refocusing on its core prostate cancer diagnostics business and establishing updated 2026 guidance of $110-115 million in revenue (20-26% YoY growth). The company also faces a $10.4 million Medicare recoupment decision from Novitas that it is contesting.

GlobeNewswire Inc.

Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

Mdxhealth announced positive data from the GPS-ProMPT study at the EAU Congress, demonstrating that its Genomic Prostate Score (GPS mdx) test successfully stratified treatment failure risk across multiple prostate cancer treatment pathways. The study of 409 patients showed excellent six-year freedom-from-failure outcomes (92-100%), supporting the test's ability to identify patients with favorable tumor biology for treatment de-escalation. The company is advancing collaboration with University of Oxford on the GPS-ProtecT study to establish GPS mdx as the first genomic classifier supported by randomized clinical trial evidence.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 14, 20231-for-10reverse split